Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Bullfrog AI Holdings, Inc. Common Stock (BFRG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: BFRG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -83.98% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 14.22M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.64 | 52 Weeks Range 1.23 - 4.84 | Updated Date 06/29/2025 |
52 Weeks Range 1.23 - 4.84 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.8 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -78.05% | Return on Equity (TTM) -141.43% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 10607832 | Price to Sales(TTM) 262.62 |
Enterprise Value 10607832 | Price to Sales(TTM) 262.62 | ||
Enterprise Value to Revenue 205.12 | Enterprise Value to EBITDA -12.02 | Shares Outstanding 9415520 | Shares Floating 7018332 |
Shares Outstanding 9415520 | Shares Floating 7018332 | ||
Percent Insiders 25.96 | Percent Institutions 4.5 |
Upturn AI SWOT
Bullfrog AI Holdings, Inc. Common Stock
Company Overview
History and Background
Bullfrog AI Holdings, Inc. is a company focused on revolutionizing drug development through its AI-driven platform. It was founded to address the challenges of identifying effective treatments and predicting patient outcomes using complex biological data. The company has evolved to offer solutions to pharmaceutical companies and research institutions.
Core Business Areas
- Drug Development Platform: Bullfrog AI offers a platform called bfLEAPu2122 that uses advanced machine learning and artificial intelligence to analyze complex biological data. This platform helps researchers identify potential drug candidates, predict patient responses, and optimize clinical trials.
- Data Analytics Services: Bullfrog AI provides data analytics services leveraging its platform to assist pharmaceutical and biotech companies in their drug discovery and development processes. This includes data integration, analysis, and interpretation to support decision-making.
Leadership and Structure
The company's leadership team includes executives with backgrounds in biotechnology, data science, and business management. The organizational structure likely involves distinct departments for research and development, data science, sales and marketing, and operations.
Top Products and Market Share
Key Offerings
- bfLEAPu2122 Platform: bfLEAPu2122 is Bullfrog AI's core AI-driven platform for analyzing complex biological data. It is used to accelerate drug discovery and predict patient outcomes. Market share data for specific AI-driven drug discovery platforms is not readily available and is emerging. Competitors include companies offering AI-driven drug discovery solutions such as Schru00f6dinger (SDGR), Recursion Pharmaceuticals (RXRX), and Exscientia (EXAI).
Market Dynamics
Industry Overview
The pharmaceutical industry is facing increasing pressure to reduce drug development costs and timelines. AI and machine learning technologies are becoming increasingly important for improving efficiency and success rates in drug discovery and clinical trials.
Positioning
Bullfrog AI aims to position itself as a key player in the AI-driven drug discovery market by providing a comprehensive platform for analyzing complex biological data and predicting patient outcomes. Their competitive advantage lies in their unique bfLEAPu2122 platform.
Total Addressable Market (TAM)
The TAM for AI in drug discovery is estimated to be in the tens of billions of dollars and is expected to grow significantly in the coming years. Bullfrog AI is positioned to capture a share of this market by providing solutions for data analysis and drug candidate identification.
Upturn SWOT Analysis
Strengths
- Proprietary AI-driven platform (bfLEAPu2122)
- Expertise in analyzing complex biological data
- Potential to accelerate drug discovery and reduce development costs
- Focus on personalized medicine and predicting patient outcomes
Weaknesses
- Limited operating history and brand recognition
- Dependence on securing contracts with pharmaceutical and biotech companies
- Intense competition in the AI-driven drug discovery market
- Relatively small size compared to major players in the industry
Opportunities
- Growing demand for AI and machine learning solutions in drug discovery
- Expanding applications of AI in personalized medicine and clinical trials
- Potential to partner with larger pharmaceutical companies
- Opportunity to expand platform capabilities and target new therapeutic areas
Threats
- Rapid technological advancements and emergence of new competitors
- Regulatory hurdles and data privacy concerns
- Potential for failure of clinical trials
- Economic downturn and reduced investment in drug development
Competitors and Market Share
Key Competitors
- SDGR
- RXRX
- EXAI
Competitive Landscape
Bullfrog AI faces significant competition in the AI-driven drug discovery market. Its advantages include its proprietary bfLEAPu2122 platform and expertise in analyzing complex biological data. Disadvantages include limited brand recognition and financial resources compared to larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends are limited and require access to private or limited public information.
Future Projections: Future growth projections require access to analyst estimates and company guidance, which are not generally available for Bullfrog AI.
Recent Initiatives: Bullfrog AI has been focused on enhancing its bfLEAPu2122 platform and securing partnerships with pharmaceutical companies and research institutions.
Summary
Bullfrog AI Holdings operates in the competitive AI-driven drug discovery market with its proprietary bfLEAPu2122 platform. The company shows promise in personalized medicine and data analysis, but its smaller size and limited financial resources pose challenges. Securing partnerships and expanding platform capabilities are critical for future growth. They need to look out for growing demand, expanding markets and technological advancements.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports (where available)
- Financial News Sources
Disclaimers:
The information provided is based on publicly available data and limited information. The analysis is for informational purposes only and should not be considered investment advice. Market share figures are estimated based on publicly available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bullfrog AI Holdings, Inc. Common Stock
Exchange NASDAQ | Headquaters Gaithersburg, MD, United States | ||
IPO Launch date 2023-02-13 | Founder, Chairman & CEO Mr. Vininder Singh | ||
Sector Healthcare | Industry Health Information Services | Full time employees - | Website https://www.bullfrogai.com |
Full time employees - | Website https://www.bullfrogai.com | ||
Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a novel formulation of mebendazole , which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebendazole, which is in the preclinical stage for the treatment of Glioblastoma; BF-114, which is in the discovery phase, to treat obesity and chronic liver diseases; and Modified HSV-1, which is in the discovery phase, for the treatment of modified colorectal cancer. The company has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. It also has a partnership with the Lieber Institute for Brain Development (LIBD) to enable the discovery and development of precision treatments for CNS disorders. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.